Connect Biopharma Holdings Limited — FY2023 Form 20-F
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter filing; the text does not provide separate Q4 financial results. Financial statements are prepared under IFRS Accounting Standards in U.S. dollars.
Business context
Connect Biopharma is a clinical-stage biopharmaceutical company developing therapies for T cell-driven inflammatory diseases. Its two clinical-stage candidates are rademikibart, an anti-IL-4Rα antibody for atopic dermatitis (AD) and asthma, and icanbelimod, an oral S1P1 modulator for inflammatory bowel disease. The company has no approved products and recognized no revenue in 2023.
Key financial metrics
| USD millions, except per-share data | 2023 | 2022 |
|---|---|---|
| Revenue recognized | 0 | 0 |
| Research and development expense | 51.9 | 96.6 |
| Administrative expense | 14.5 | 20.8 |
| Operating loss | 62.1 | 119.3 |
| Net loss | 59.5 | 118.1 |
| Basic and diluted loss per share | $1.08 | $2.15 |
| Net cash used in operating activities | 47.9 | 101.5 |
| Cash and cash equivalents, year-end | 106.0 | 79.0 |
| Short-term investments, year-end | 12.6 | 73.4 |
| Total assets / total liabilities, year-end | 125.9 / 24.8 | 174.0 / 16.5 |
Year-end net assets were $101.0 million; accumulated losses were $539.3 million. The company reported no debt outstanding and no material capital commitments. A conventional profit margin is not meaningful because the company has no product revenue and remains loss-making. Management said cash, cash equivalents, and short-term investments were expected to fund operating needs for at least 12 months from the financial-statement issuance date.
Investing activities generated $75.2 million in 2023, mainly reflecting maturities of investments; financing activities used $0.2 million, primarily for lease payments. Lease liabilities were $0.5 million at year-end. The $13.3 million Simcere upfront amount received by year-end was recorded as a contract liability, not recognized as revenue.
Material changes versus 2022
- Net loss narrowed by $58.6 million, and operating cash use declined by $53.6 million.
- R&D expense fell $44.7 million, mainly because clinical-trial and drug-manufacturing activity declined; company-reported candidate-specific clinical-trial expense also fell for both rademikibart and icanbelimod.
- Administrative expense decreased $6.3 million, reflecting lower professional-service and personnel costs.
- Cash and cash equivalents increased by $27.0 million, while short-term investments fell $60.8 million, primarily in connection with investment maturities and purchases.
- The $4.7 million impairment recorded in 2022 did not recur. It related to construction-in-progress assets after the company discontinued plans for a Taicang research, manufacturing, and office facility.
Outlook, commentary, and risks
- Rademikibart: The China pivotal AD trial met primary and key secondary endpoints in Stage 1; reported maintenance results through 52 weeks were positive for both every-four-week and every-two-week dosing. A global Phase 2b asthma trial met its primary endpoint, with placebo-adjusted FEV1 improvements at Week 12 of 140 ml and 189 ml for the 150 mg and 300 mg groups, respectively. The company planned 2024 regulatory discussions on possible global Phase 3 programs; these were plans, not approvals or guaranteed trial starts.
- Simcere agreement: Simcere received exclusive Greater China rights to develop, manufacture, and commercialize rademikibart. The agreement provides a RMB 150 million upfront payment, up to RMB 875 million in development and commercial milestones, and royalties up to low double-digit percentages. A further RMB 50 million upfront installment was received in Q1 2024. Future milestones and royalties are contingent; the filing says failure of specified PRC trial endpoints could permit termination.
- Icanbelimod: The Phase 2 UC induction trial did not meet statistical significance on its primary clinical-response endpoint, although a clinical-remission measure was statistically significant. Among patients who achieved remission at Week 12, 80% reportedly maintained remission through Week 48. The company was seeking an out-licensing partner for further UC and Crohn’s disease development.
- Funding: Management expects continued losses and says existing capital is insufficient to fund all candidates through approval. The company may need additional financing, licensing, or partnerships. An effective shelf registration covers up to $300 million, including up to $150 million through an at-the-market program; no sales under it had occurred by year-end.
- Clinical and operating risks: Drug development, regulatory approval, patient enrollment, safety, third-party manufacturing, and partner execution are uncertain. The Russia-Ukraine war disrupted trial activity and data collection at some sites; COVID-19-related enrollment challenges ended the Phase 2 Crohn’s disease trial early.
- PRC and market risks: The filing highlights uncertainty around PRC data, human genetic resources, regulatory and securities-filing rules, cross-border fund transfers, and foreign-exchange controls. A future loss of PCAOB inspection access could create HFCAA trading and delisting risk; the PCAOB had restored access in December 2022, and the company did not expect identification under the HFCAA absent a new determination.
- Safety and unusual items: A healthy volunteer in an early icanbelimod study experienced treatment-related bradycardia with transient asystole and recovered. In 2021, a phishing payment incident caused a $1.1 million loss; some insurance recovery was received. No material cybersecurity incident was reported for 2023. The company changed its presentation currency from RMB to U.S. dollars retrospectively beginning with 2021 comparative figures.
Important facts for investors to verify
- Review the audited IFRS statements and notes for cash availability, investment maturities, contract liabilities, and the company’s stated 12-month liquidity assessment.
- Track regulatory feedback and any actual initiation, design, and funding of proposed rademikibart Phase 3 trials, as well as Simcere’s China filing progress and the conditions attached to milestone payments.
- Assess final and complete icanbelimod trial data, the implications of the missed primary UC endpoint, and whether a development partner is secured.
- Monitor financing needs, potential dilution from the shelf or at-the-market program, and progress toward revenue recognition under the Simcere agreement.
- Confirm the continued effectiveness of financial controls and monitor clinical safety, trial-site disruption, third-party supply, PRC regulatory developments, and audit-inspection access.